TargeOn SAS, a French company specialized in the development and commercialization of pediatric medicines, today announced that the company will be renamed ORPHELIA Pharma SA, effective October 9th, 2015. The articles of incorporation have been amended accordingly.
“The change of our company name is made to better reflect our activities in the field of rare pediatric indications” says Hugues Bienaymé, CEO and Founder of ORPHELIA Pharma. “This change is also the opportunity to launch our new website, to improve information on future developments of ORPHELIA Pharma and to facilitate the establishment of partnerships in Europe and North America.”
Founded in 2007 by Hugues Bienaymé and previously known as TargeOn SAS, ORPHELIA Pharma’s mission is to develop and market new pediatric formulations of drugs already approved in Europe or in the USA. The company intends to use the regulation on pediatric medicines enacted in 2006 in Europe, including notably the PUMA (Pediatric Use Marketing Authorization) regulation. ORPHELIA Pharma holds several projects within the pediatric neurology field, notably anti-epileptic drugs. The most advanced project is currently in clinical development stage in France.